Remibrutinib CSU Competitive Landscape — Comprehensive Study Notes

Training context and regulatory notes

• This material is for training purposes only. Do not copy, share, or discuss outside of Novartis materials. No comparisons or claims of superiority between Novartis and competitors in customer discussions.
• If a customer asks a question outside current approved materials, use a medical inquiry and consider MSL on demand in the future.
• Remibrutinib (Remibrutinib/Remibrutinib) is investigational and should not be discussed in the field until FDA approval; monitor for future communications about approval.
• If any questions arise, staff were advised to direct to MSLs and approved materials.

Key players in CSU (chronic spontaneous urticaria) landscape

• Main competitors discussed: Dupixent (dupilumab) and Xolair (omalizumab).
• Remibrutinib positioned as a next-gen BTK inhibitor with potential to address both major CSU endotypes.
• Dupixent and Xolair are long-standing, widely used therapies with extensive clinical experience and regulatory approvals in multiple countries.

Timeline and indications: Xolair vs Dupixent

• Xolair (omalizumab) indications timeline (as described):
  • 2003: Approved for adults with asthma.
  • ~2013: Approved for CSU in adults.
  • 2020: Chronic rhinosinusitis with nasal polyps (CRSwNP).
  • 2024: IgE-mediated food allergies in patients aged 1 year and older.
  • Total indications: 4 (as summarized in the deck).
• Dupixent (dupilumab) indications timeline (as described):
  • 2017: Atopic dermatitis (AD) in adults.
  • 2018: Asthma (adults).
  • 2019: Chronic rhinosinusitis with nasal polyps (CRSwNP).
  • 2022: AD indication extended to younger ages (6 months and older) and expanded other allergic conditions, including pediatric asthma and EoE (eosinophilic esophagitis) updates; indications expanded over time to at least 8 across various allergic diseases by the time of the talk.
• Global approvals: Dupixent approved in >60 countries; Xolair approved in >90 countries.
• Practical takeaway: Dupixent has broader leading indications across allergic diseases; Xolair is highly established in IgE-mediated pathways with strong real-world familiarity among providers.

Mechanisms of action: how each drug works

• Xolair (omalizumab):
  • Mechanism: Humanized monoclonal antibody that binds free IgE in the serum, preventing IgE from attaching to FcεRI receptors on mast cells and other effector cells.
  • Consequence: Reduced free IgE leads to downregulation of FcεRI receptors on mast cells over time, decreasing allergic activation.
• Dupixent (dupilumab):
  • Mechanism: Monoclonal antibody that targets the IL-4 receptor alpha subunit (IL-4Rα), blocking signaling of both IL-4 and IL-13.
  • Consequence: Reduces IgE production by B cells (downstream effect on allergic inflammation) and dampens multiple downstream Th2-driven pathways.
• Remibrutinib (BTK inhibitor; investigational for CSU):
  • Mechanism: Highly selective BTK (Bruton's tyrosine kinase) inhibitor that acts intracellularly within mast cells and B cells.
  • Dual endotype coverage: Inhibits signaling relevant to both IgE-mediated (type 1) and autoimmune IgG-mediated (type 2B) CSU pathways, addressing both major CSU endotypes.
  • Analogy used in training: Mast cells are like an iPhone receiving notifications (IgE apps) and IL-4/IL-13 signals are like spam messages; BTK inhibition reduces the cascade that leads to degranulation and mediator release.
• Practical implication: Remibrutinib’s intracellular action and dual endotype coverage may offer advantages in patients who respond variably to anti-IgE or IL-4/IL-13 pathway–targeted therapies.

Dosing, formulations, and administration

• Dupixent (dupilumab) dosing overview:
  • Adults: Initial loading dose of $600\,\mathrm{mg}$ (two injections of $300\,\mathrm{mg}$), followed by $300\,\mathrm{mg}$ every two weeks.
  • Pediatric dosing by weight (
  • If <60 kg: loading $400\,\mathrm{mg}$, then $200\,\mathrm{mg}$ every two weeks.
  • If ≥60 kg: similar to adult dosing (i.e., $600\,\mathrm{mg}$ loading followed by $300\,\mathrm{mg}$ every two weeks).
  • Formulations: prefilled syringe with needle shield or prefilled single-dose pen.
• Xolair (omalizumab) dosing overview:
  • CSU indication dosing commonly $300\,\mathrm{mg}$ every $4\,\mathrm{weeks}$; can start with $150\,\mathrm{mg}$ every 4 weeks in CSU, though $150\,\mathrm{mg}$ is less commonly used in CSU.
  • Administration: can be given as a single $300\,\mathrm{mg}$ injection or as two separate $150\,\mathrm{mg}$ injections.
  • Formulations: prefilled syringe; auto-injector; lyophilized powder for reconstitution.
• Remibrutinib dosing (as described for trials):
  • Oral BTK inhibitor regimen used in CSU trials: typically multiple dosing regimens (e.g., $25\,\mathrm{mg}$ twice daily in the study context; exact labeling may differ in development programs).
• Practical note on administration preference:
  • Oral therapy (Remibrutinib) offers a convenient alternative for patients who dislike injections.
  • Injectables (Dupixent, Xolair) remain standard for patients who prefer or respond best to biologics.

Trial designs and comparative contexts

• REMICS program (Remibrutinib CSU):
  • Phase 3, double-blind, placebo-controlled trials in adults with CSU inadequately controlled on second-generation H1 antihistamines.
  • Randomization: 2:1 ratio (more patients assigned to remibrutinib than placebo).
  • Duration: 24 weeks double-blind phase; 28 weeks total with open-label extension; then extension to week 52 in some arms.
  • Background therapy: all patients on background antihistamines; rescue antihistamines allowed up to 4 times daily.
  • Dosing in trials: 25 mg twice daily (Remibrutinib) described in the talk; objective was to assess efficacy vs placebo.
• Xolair CSU trials (Asteria 1 & 2, Glacial):
  • Age range: 12–75 years.
  • Design: randomized, placebo-controlled trials with a similar background antihistamine and rescue antihistamine framework.
  • Glacial allowed additional background meds such as leukotriene receptor antagonists and H2 blockers; Asteria trials generally allowed antihistamines with rescue options.
  • Primary endpoint: usually at week 12 for CSU indications.
• Dupixent CSU program (CUPID A, B, C):
  • Phase 3, double-blind, placebo-controlled.
  • Study A: Xolair naive; Study B: Xolair intolerant or nonresponsive (Xolair refractory); Study C: Xolair naive.
  • Screening randomization: Dupixent + background antihistamines vs placebo + background antihistamines.
  • Sample sizes: CUPID A = 138; CUPID B = 108; CUPID C = 151.
  • Endpoints: primary at week 24 (longer than REMICS and Asteria/Glacial); rescue antihistamines allowed up to 4 times daily.
• Cross-trial cautions:
  • Do not directly compare efficacy numbers across trials due to differing populations, timepoints, and background therapies.
  • REMICS included anti-IgE-experienced patients (a third had prior anti-IgE exposure); Xolair CSU trials did not include anti-IgE failures by design.

Efficacy outcomes: comparing key endpoints across programs

• Urticaria Activity Score (UAS7) and related measures:
  • Change from baseline at the primary endpoint (week 12 for REMICS and Asteria/Glacial; week 24 for CUPID):
  • Remibrutinib (REMICS): approx. ΔUAS7 ≈ −20 versus placebo ≈ −13 in the first REMICS trial; similar magnitude in Remix 2; large delta favoring Remibrutinib.
  • Dupixent (CUPID A, C): ΔUAS7 ≈ −20 to −15 in CUPID A/C with strong separation from placebo; CUPID B (Xolair-exposed failures) showed less robust or non-significant improvements in some endpoints.
  • Xolair (Asteria/Glacial): ΔUAS7 ≈ −20 to −21 in multiple arms; generally strong reductions versus placebo.
  • Itch severity (ISS7) and Hives severity (HHS7):
  • REMICS: significant reductions vs placebo; some CUPID/B arms showed non-significant results depending on endotype and prior therapy status.
  • Xolair: broadly favorable reductions in ISS7 and HHS7 across trials.
  • Proportion achieving well-controlled urticaria (UAS7 ≤ 6):
  • REMICS: ~47–49% in some arms; ~30% in several arms depending on trial row.
  • CUPID A/C (Dupixent naive): around 30% in some arms; CUPID B (Xolair failures) lower in that arm.
  • Xolair: higher percentages in several arms, e.g., ~52–66% across some comparisons.
  • Complete control (UAS7 = 0) at endpoint:
  • REMICS: about 31% (REMICs) in some arms.
  • CUPID A/C: around 30% in several arms; CUPID B lower (around 13%).
  • Xolair: around 35–44% in some arms; ~34% in another arm.
• Overall interpretation highlighted in the training:
  • Efficacy of Remibrutinib is broadly on par with Xolair and Dupixent across major endpoints in CSU, with nuances due to differences in patient populations (e.g., prior anti-IgE exposure) and endpoints timing.
  • Dupixent showed robust efficacy in anti-IgE–naive patients (CUPID A/C) but some subgroup (CUPID B) of Xolair-refractory patients did not reach statistical significance, highlighting pathway-specific responses.
  • The data suggest Remibrutinib’s dual endotype coverage (IgE and IgG pathways) may offer advantages in patients with autoimmune CSU endotypes not fully responsive to IgE-blockade alone.

Safety, warnings, and tolerability

• Overall safety signals:
  • Discontinuation due to study treatment: Remibrutinib ≈ 2.8%; Dupixent ≈ 1.6%; Xolair ≈ 1.26% (varies by program).
  • Common adverse events across programs include nasopharyngitis, headache, and sinusitis; overall rates were modest.
• Program-specific warnings and notable safety considerations:
  • Dupixent: hypersensitivity risk; conjunctivitis and keratitis (more common in some indications); potential eosinophilic conditions; caution with abrupt steroid withdrawal; parasitic infections risk; vaccination considerations (avoid live vaccines during treatment).
  • Xolair: Black box warning for anaphylaxis; first 3 doses commonly administered in a healthcare setting due to anaphylaxis risk; malignancy signal (~0.5% in trials; data across ~4000+ treated patients); acute asthma symptoms should not be treated with IV Xolair; do not abruptly discontinue steroids; eosinophilic conditions can emerge; not for emergency treatment of anaphylaxis.
• Comparative safety notes:
  • In CSU trials, safety profiles for all three agents were generally favorable and well tolerated; Remibrutinib currently has less long-term safety data versus well-established biologics, though early data are favorable.

Practical and clinical implications

• Endotype-driven treatment decisions in CSU:
  • Type 1 CSU (IgE-mediated) vs Type 2B CSU (autoimmune IgG–mediated) differ in responsiveness to different therapies.
  • Xolair primarily targets IgE pathway; Dupixent primarily targets IL-4/IL-13 axis; Remibrutinib targets BTK, affecting both pathways and cells involved (mast cells, B cells, and others).
  • Remibrutinib may be advantageous in patients with autoimmune CSU endotype or prior IgE-targeted therapy failure.
• Onset of action and time to endpoint:
  • Dupixent CUPID primary results at week 24; Remibrutinib data show rapid onset (as early as week 1 in some analyses) in CSU, which can be a differentiating talking point for clinicians and patients seeking quicker relief.
  • Xolair demonstrates meaningful improvement by week 12 in CSU trials.
• Patient preferences and administration burden:
  • Oral therapy (Remibrutinib) may improve adherence for some patients who dislike injections.
  • Injectable biologics (Dupixent, Xolair) remain widely accepted and familiar to many patients and clinicians.
• Regulatory and labeling considerations:
  • Head-to-head data between Remibrutinib and Dupixent or Xolair are limited; ongoing trials include head-to-head designs and ongoing analyses for earlier time points.
  • Washout considerations: current internal discussions in trials suggest a four-month washout when switching from Xolair to Remibrutinib, but the label and routine clinical practice may vary; still to be confirmed in labeling.
• Practical caveats for practice:
  • Testing requirements for CSU start: No testing required to start Xolair or Dupixent for CSU; some tests are required for asthma/food allergy indications but not for CSU.
  • Concomitant immunotherapies and infections: No data indicating increased immunosuppression with these CSU therapies; monitor accordingly per standard practice.

Real-world questions, interpretations, and expert insights (highlights from the Q&A)

• How to explain Remibrutinib’s immune effects to clinicians and patients:
  • Emphasize selectivity: Remibrutinib is highly selective for BTK; minimizes impact on other tyrosine kinase pathways, reducing infection risk concerns.
  • Safety profile: Early safety data show no increased infections versus placebo, even during the COVID-19 era.
  • Mechanistic breadth: BTK inhibition blocks both IgE- and IgG-mediated pathways, addressing both endotypes and potentially reducing disease activity more comprehensively.
• Is there evidence of IgG pathway involvement with Remibrutinib?:
  • The data suggest BTK inhibition can affect both IgE and IgG–mediated signaling within mast cells and B cells, but specific quantitative IgG measurements and neutralizing antibody data in CSU trials are not extensively published yet.
• Do prior anti-IgE (Xolair) failures predict response to Remibrutinib or Dupixent?
  • Prior anti-IgE failure status can influence response heterogeneity across trials; CUPID B (Dupixent) included Xolair-refractory patients with less consistent efficacy signals, illustrating pathway-specific responsiveness.
• Are there any testing requirements before starting these CSU therapies?
  • For CSU indications specifically, no testing is required to initiate Xolair or Dupixent.
  • Testing (e.g., for asthma/food allergies) may be required for other indications, but not mandated for CSU therapy initiation according to the materials.
• What do meta-analyses suggest about Remibrutinib vs anti-IgE therapies for CSU?
  • A prominent meta-analysis (Jackie et al., JACI, July issue) suggests Remibrutinib is equivalent to omalizumab in CSU outcomes such as urticaria activity, angioedema, and quality of life, supporting the potential of BTK inhibition as a strong competitor in CSU management.
• Is there a potential for Remibrutinib to be used as an adjunct to Xolair or Dupixent?
  • Current material frames Remibrutinib as an alternative with potentially broader endotype coverage; off-label combination use is not described in the labeling and would be subject to clinical judgment and future trial data.
• What are the practical implications of endotype underscores for patient counseling?
  • Convey that CSU is heterogeneous; some patients respond best to anti-IgE therapy (Xolair), others to IL-4/IL-13 blockade (Dupixent), and Remibrutinib may address both endotypes for broader efficacy; set expectations about response timelines and need for ongoing monitoring.
• What are known limitations or data gaps to watch for?
  • Long-term safety data for Remibrutinib relative to established biologics; direct head-to-head data between Remibrutinib and other therapies; data in younger populations; real-world adherence and rescue-therapy usage patterns; immunogenicity and neutralizing antibodies require further data.

Key takeaways for exam preparation and clinical discussion

• Remibrutinib represents a BTK-inhibitor approach with dual pathway coverage (IgE and IgG) for CSU, offering potentially rapid onset of action and an oral administration option.
• Dupixent and Xolair remain well-established CSU therapies with robust safety profiles; Dupixent targets the IL-4/IL-13 axis, while Xolair reduces free IgE and downstream receptor expression.
• Efficacy data across CSU programs show substantial improvements in UAS7, ISS7, and HSS7 with all three agents; differences across trials reflect patient populations, prior therapies, and endpoint timing (week 12 vs week 24).
• Safety and tolerability are favorable for all three programs, but each has unique warnings (e.g., anaphylaxis with Xolair; conjunctivitis/keratitis with Dupixent).
• Clinical decision-making in CSU should consider endotype (type 1 vs type 2B), patient preferences for oral vs injectable therapy, prior therapy history (including anti-IgE exposure), and practical considerations such as dosing frequency and setting for initiation of therapy.
• Industry-context reminders: training materials emphasize confidentiality and adherence to approved materials; ongoing trials and data will shape labeling and real-world use.

Glossary of key terms (quick reference)

• CSU: Chronic spontaneous urticaria.
• UAS7: Urticaria Activity Score over 7 days (higher scores = more activity).
• ISS7: Itch severity score over 7 days.
• HHS7: Hives severity score over 7 days.
• BTK: Bruton's tyrosine kinase, a signaling protein in B cells and mast cells; target of remibrutinib.
• IgE: Immunoglobulin E, central to allergic pathways.
• IgG: Immunoglobulin G, involved in autoimmune pathways in CSU endotypes (type 2B).
• IL-4/IL-13: Cytokines driving Th2 allergic inflammation; targets of Dupixent.
• Endotype: A disease subtype defined by distinct pathobiology (e.g., type 1 IgE-mediated vs type 2B autoimmune CSU).
• Loading dose: Initial higher dose to rapidly achieve therapeutic levels (as with Dupixent 600 mg).
• Rescue therapy: Short-term additional medications used to manage acute symptoms (e.g., extra antihistamines during CSU flares).
• Live vaccines: Vaccination caution with some biologics; avoid live vaccines during Dupixent use.

Notes on how to study this content efficiently

• Use the mechanism-of-action contrasts to understand why different therapies may work better for different CSU endotypes.
• Memorize key dosing examples for Dupixent and Xolair (adult and pediatric where applicable) as they frequently appear in exam questions.
• Be able to interpret efficacy endpoints (UAS7, ISS7, UAS7=0) and recognize that direct cross-trial comparisons are limited by design differences.
• Remember the regulatory and practical context: Remibrutinib is investigational in the material; current clinical practice for CSU centers on Dupixent and Xolair with well-established safety profiles; monitor for updates on labeling and approvals.

End of notes